Evaluation of the Integrated Intervention for Dual Problems and Early Action Among Latino Immigrants With Co-occurring Mental Health and Substance Misuse Symptoms

Margarita Alegría, Irene Falgas Bague, Francisco Collazos Sanchez, Rodrigo Carmona Camacho, Sheri Lapatin Markle, Ye Wang, Enrique Baca-García, Benjamin Lê Cook, Ligia M. Chavez, Lisa Fortuna, Lizbeth Herrera, Adil Qureshi, Zorangeli Ramos, Claudia González, Paloma Aroca, Lucía Albarracín García, Lucía Cellerino, A Villar, Naomi Ali, Kim T. MueserPatrick E. Shrout

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

17 Citas (Scopus)

Resumen

Would a tailored behavioral health intervention reduce substance misuse and mental health symptoms, compared with enhanced usual care, in Latino immigrants with co-occurring mental health and substance misuse symptoms? In this randomized clinical trial from 3 sites of 341 immigrants with co-occurring mental health and substance misuse symptoms, the primary outcome of substance misuse did not change in the intent-to-treat analysis. Patients who received the treatment statistically significantly experienced decreased mental health symptoms, compared with controls under enhanced usual care, and only participants with moderate to severe symptoms who received the intervention statistically significantly reduced their substance misuse. The intervention did not change drug misuse in a heterogeneous sample but did improve secondary mental health outcomes, a finding that might provide a path for treating Latino immigrants with co-occurring mental health symptoms whose symptoms are in the moderate-to-severe range. Immigrants are at an increased risk for co-occurring mental health and substance misuse symptoms; however, effective treatments are lacking. To evaluate the effectiveness of the Integrated Intervention for Dual Problems and Early Action (IIDEA) program compared with enhanced usual care. This effectiveness randomized clinical trial was conducted from September 2, 2014, to February 2, 2017, in 17 clinics or emergency departments and 24 community sites in Boston, Massachusetts, as well as in Madrid and Barcelona, Spain. Equal randomization (1:1) in 2-person blocks was used, assigning participants to either the IIDEA treatment group (n = 172) or the enhanced usual care control group (n = 169). Intent-to-treat analyses assessed effectiveness, and post hoc analyses examined whether results varied by symptom severity or treatment dose. Eligible participants were between 18 and 70 years of age, self-identified as Latino, screened positive for co-occurring symptoms, and were not receiving specialty behavioral health services. Participants were randomized to a 10-session IIDEA treatment or to enhanced usual care. Primary outcomes were changes in alcohol and drug misuse and results of a urine test for drug metabolites but not for alcohol misuse. Secondary outcomes were symptoms of depression, generalized anxiety, posttraumatic stress disorder, and overall mental health. In total, 341 participants were randomized to either the IIDEA treatment group (n = 172; 94 [54.7%] female, mean [SD] age, 33.5 [11.6] years) or the enhanced usual care control group (n = 169; 80 [47.3%] female, mean [SD] age, 34.3 [11.8] years). No statistically significant effects of IIDEA were found for primary drug and alcohol outcomes (ASI Lite-drug score: β = −0.02 [SE, 0.69; P = .88; Cohen d, 0.00; 95% CI, −0.17 to 0.17]; ASI Lite-alcohol score: β = −0.01 [SE, 1.19; P = .66; Cohen d, 0.00; 95% CI, −0.12 to 0.12]; urine drug test result: β = −0.36 [SE, 0.43; P = .50; OR, 0.70; 95% CI, 0.30-1.61]), but statistically significant effects were observed for secondary mental health outcomes. The IIDEA treatment was effective in reducing depressive symptoms per the Patient Health Questionnaire-9 score (β = −1.14; SE, 0.47; P = .02; Cohen d, 0.20 [95% CI, 0.04-0.36]), posttraumatic stress disorder symptoms per the Posttraumatic Stress Disorder Checklist-5 score (β = −3.23; SE, 1.59; P = .04; Cohen d, 0.25 [95% CI, 0.01-0.37]), and overall mental health symptoms per the Hopkins Symptom Checklist-20 (β = −0.20; SE, 0.07; P = .01; Cohen d, 0.25 [95% CI, 0.08-0.42]) and composite mental health (β = −3.70; SE, 1.75; P = .04; Cohen d, 0.19 [95% CI, 0.01-0.36]) scores at the 6-month follow-up. Exploratory analyses suggested that 6-month treatment effects occurred for patients whose drug misuse was moderate to severe at the baseline assessment. Among patients with moderate to severe substance misuse, IIDEA substantially reduced substance use per the urine test results (odds ratio, 0.25 [95% CI, 0.09-0.67]; P = .01). Treatment dose showed small to large effect sizes by outcome. The IIDEA treatment did not change drug misuse but did improve secondary mental health and substance misuse outcomes for a heterogeneous population with moderate to severe symptoms; this finding provides a path for treating Latino immigrants with co-occurring mental health and substance misuse symptoms. ClinicalTrials.gov Identifier: This randomized clinical trial evaluates the effectiveness of an integrated, multiyear cognitive behavior therapy, the Integrated Intervention for Dual Problems and Early Action (IIDEA), compared with enhanced usual care among Latino immigrants with dual mental health and substance misuse symptoms.
Idioma originalInglés
PublicaciónJAMA network open
Volumen2
DOI
EstadoPublicada - 2019

Huella

Profundice en los temas de investigación de 'Evaluation of the Integrated Intervention for Dual Problems and Early Action Among Latino Immigrants With Co-occurring Mental Health and Substance Misuse Symptoms'. En conjunto forman una huella única.

Citar esto